TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$50.39
−0.36%Oct 26, 2026, 20:30 UTC
Travere Therapeutics announced that it will report its third-quarter 2026 financial results on November 2, 2026, after U.S. markets close, and host a conference call and webcast at 4:30 p.m. ET.
Source:Oct 23, 2026, 23:20 UTC
Travere Therapeutics presented new Phase 3 Travere Therapeutics, Inc. biomarker data on FILSPARI in IgA nephropathy at ASN Kidney Week 2026.
Source:Oct 2, 2026, 14:00 UTC
Travere Therapeutics announced it will present nine new data presentations, including five oral presentations, on FILSPARI (sparsentan) in IgA nephropathy and FSGS at ASN Kidney Week 2026 in Denver, October 21-25.
Source:Sep 30, 2026, 13:58 UTC
Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Travere Therapeutics, Inc. breached their fiduciary duties to shareholders.
Source:Sep 23, 2026, 11:00 UTC
The U.S. Patent and Trademark Office issued a Notice of Allowance for Travere Therapeutics' U.S. Patent Application No. 19/253,120 covering certain methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis.
Sep 21, 2026, 20:17 UTC
Travere Therapeutics appointed Bradley L. Campbell as President and Chief Executive Officer effective December 1, 2026.
Sep 21, 2026, 20:06 UTC
Travere Therapeutics CEO Eric Dube will step down in December 2026.
Aug 18, 2026, 10:03 UTC
Travere Therapeutics reported that the launch of FILSPARI for focal segmental glomerulosclerosis (FSGS) exceeded expectations, and the company is expanding its renal pipeline.
Source:Aug 4, 2026, 22:16 UTC
Travere Therapeutics reported a second-quarter loss of $0.37 per share, missing the Zacks Consensus Estimate of a loss of $0.14, and compared to a loss of $0.14 per share a year ago.
Jun 16, 2026, 00:00 UTC
William Rote, Ph.D. retired as Chief Research Officer of Travere Therapeutics, effective 2027-02-17.
Jun 4, 2026, 04:00 UTC
Everest Medicines entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a BTK inhibitor for rare kidney diseases.
Source:Jun 2, 2026, 00:00 UTC
Travere Therapeutics entered into a license and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib (EVER001) outside China and select East and Southeast Asia.